CELL Response careers

Current drugs do not mitigate patient tumor resistance and therefore provide limited survival to cancer patients. Our platform technology enables the develop drugs to overcome resistance/relapse of late-stage cancer patients – A big unmet need in cancer treatment. We aim to be a clinical stage biotech dedicated to combat relapse.

We will utilize the technology to develop (i) 1st line drugs with minimal provoked resistance. (ii) 2nd line drugs to combat resistance of already approved drugs. Revenue will be generated through 4 different drivers.
1. Platform licensing (Partnering /Service) to biotech/pharma.
2. In-house drug development and drug rescue.
3. Drug repositioning of approved drugs to combat resistance.
4. Licensing out drug targets and use of resistant cell clones to biotech/pharma